We currently don't have sufficient analyst coverage to forecast growth and revenue for MINAPHARM Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth
13.5%
Revenue growth rate
n/a
Future return on equity
n/a
Analyst coverage
None
Last updated
n/a
Recent future growth updates
No updates
Recent updates
In this section we usually present revenue and earnings growth
projections based on the consensus estimates of professional
analysts to help investors understand the company’s ability to
generate profit. But as MINAPHARM Pharmaceuticals has not provided enough
past data and has no analyst forecast, its future earnings
cannot be reliably calculated by extrapolating past data or
using analyst predictions.
This is quite a rare situation as 97% of companies covered by
SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
CASE:MIPH - Analysts future estimates and past financials data (EGP Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2025
6,438
7
-327
465
N/A
9/30/2025
6,924
112
-440
377
N/A
6/30/2025
6,936
221
-426
369
N/A
3/31/2025
6,288
166
-853
13
N/A
12/31/2024
5,600
128
-698
222
N/A
9/30/2024
4,423
-127
-715
160
N/A
6/30/2024
3,916
-259
-694
231
N/A
3/31/2024
3,904
-154
-897
95
N/A
12/31/2023
3,892
-55
-1,303
102
N/A
9/30/2023
4,025
281
-1,376
217
N/A
6/30/2023
4,003
461
-1,312
330
N/A
3/31/2023
3,794
529
-1,144
450
N/A
12/31/2022
3,621
590
-600
562
N/A
9/30/2022
3,442
544
-443
429
N/A
6/30/2022
3,212
467
-334
349
N/A
3/31/2022
3,032
454
-79
393
N/A
12/31/2021
3,005
448
-182
207
N/A
9/30/2021
2,918
422
4
281
N/A
6/30/2021
2,754
398
235
442
N/A
3/31/2021
2,583
325
170
359
N/A
12/31/2020
2,361
285
284
437
N/A
9/30/2020
2,200
271
305
487
N/A
6/30/2020
2,115
216
225
417
N/A
3/31/2020
2,080
174
188
381
N/A
12/31/2019
2,051
141
-39
206
N/A
9/30/2019
1,917
86
N/A
156
N/A
6/30/2019
1,936
67
N/A
104
N/A
3/31/2019
1,948
81
N/A
269
N/A
12/31/2018
1,919
116
N/A
334
N/A
9/30/2018
1,928
156
N/A
240
N/A
6/30/2018
1,820
186
N/A
107
N/A
3/31/2018
1,717
198
N/A
-8
N/A
12/31/2017
1,646
175
N/A
-4
N/A
9/30/2017
1,493
65
N/A
267
N/A
6/30/2017
1,325
55
N/A
316
N/A
3/31/2017
1,190
35
N/A
355
N/A
12/31/2016
1,035
33
N/A
436
N/A
9/30/2016
1,023
86
N/A
188
N/A
6/30/2016
1,019
97
N/A
258
N/A
3/31/2016
1,001
110
N/A
238
N/A
12/31/2015
966
83
N/A
161
N/A
9/30/2015
916
85
N/A
147
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MIPH's forecast earnings growth is above the savings rate (15.1%).
Earnings vs Market: Insufficient data to determine if MIPH's earnings are forecast to grow faster than the EG market
High Growth Earnings: Insufficient data to determine if MIPH's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MIPH's revenue is forecast to grow faster than the EG market.
High Growth Revenue: Insufficient data to determine if MIPH's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MIPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/06 22:52
End of Day Share Price
2026/07/06 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MINAPHARM Pharmaceuticals is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.